Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus

Maria Lucia Specchia; Chiara De Waure; Gualano; A Doria; G Turchetti; L Pippo; Francesco Di Nardo; Silvio Capizzi; Chiara Cadeddu; F Kheiraoui; L Iaccarino; F Pierotti; I Palla; Maria Assunta Veneziano; Maria Daniela Gliubizzi; Antonella Sferrazza; Nicola Nicolotti; R Porcasi; Giuseppe La Torre; Maria Luisa Di Pietro; Walter Ricciardi

doi:10.1155/2014/704207

Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus

Maria Lucia Specchia
, Chiara De Waure
, Gualano
, A Doria
, G Turchetti
, L Pippo
, Francesco Di Nardo
, Silvio Capizzi
, Chiara Cadeddu
, F Kheiraoui
, L Iaccarino
, F Pierotti
, I Palla
, Maria Assunta Veneziano
, Maria Daniela Gliubizzi
, Antonella Sferrazza
, Nicola Nicolotti
, R Porcasi
, Giuseppe La Torre
, Maria Luisa Di Pietro

Walter Ricciardi

Sapienza University

Research output: Contribution to journal › Article

21 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy.

Original language	English
Pages (from-to)	704207-704215
Number of pages	9
Journal	BioMed Research International
Volume	2014
Issue number	N/A
DOIs	https://doi.org/10.1155/2014/704207
Publication status	Published - 2014

All Science Journal Classification (ASJC) codes

General Biochemistry,Genetics and Molecular Biology
General Immunology and Microbiology

Keywords

HTA
Lupus

Access to Document

10.1155/2014/704207

Cite this

Specchia, M. L., De Waure, C., Gualano, Doria, A., Turchetti, G., Pippo, L., Di Nardo, F., Capizzi, S., Cadeddu, C., Kheiraoui, F., Iaccarino, L., Pierotti, F., Palla, I., Veneziano, M. A., Gliubizzi, M. D., Sferrazza, A., Nicolotti, N., Porcasi, R., La Torre, G., ... Ricciardi, W. (2014). Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. BioMed Research International, 2014(N/A), 704207-704215. https://doi.org/10.1155/2014/704207

@article{0472c7d343014d9b92c701aa398f26bb,

title = "Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus",

abstract = "Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy.",

keywords = "HTA, Lupus, HTA, Lupus",

author = "Specchia, \{Maria Lucia\} and \{De Waure\}, Chiara and Gualano and A Doria and G Turchetti and L Pippo and \{Di Nardo\}, Francesco and Silvio Capizzi and Chiara Cadeddu and F Kheiraoui and L Iaccarino and F Pierotti and I Palla and Veneziano, \{Maria Assunta\} and Gliubizzi, \{Maria Daniela\} and Antonella Sferrazza and Nicola Nicolotti and R Porcasi and \{La Torre\}, Giuseppe and \{Di Pietro\}, \{Maria Luisa\} and Walter Ricciardi",

year = "2014",

doi = "10.1155/2014/704207",

language = "English",

volume = "2014",

pages = "704207--704215",

journal = "BioMed Research International",

issn = "2314-6133",

publisher = "John Wiley and Sons Ltd",

number = "N/A",

}

Specchia, ML, De Waure, C, Gualano, Doria, A, Turchetti, G, Pippo, L, Di Nardo, F, Capizzi, S, Cadeddu, C, Kheiraoui, F, Iaccarino, L, Pierotti, F, Palla, I, Veneziano, MA, Gliubizzi, MD, Sferrazza, A, Nicolotti, N, Porcasi, R, La Torre, G, Di Pietro, ML & Ricciardi, W 2014, 'Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus', BioMed Research International, vol. 2014, no. N/A, pp. 704207-704215. https://doi.org/10.1155/2014/704207

TY - JOUR

T1 - Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus

AU - Specchia, Maria Lucia

AU - De Waure, Chiara

AU - Gualano,

AU - Doria, A

AU - Turchetti, G

AU - Pippo, L

AU - Di Nardo, Francesco

AU - Capizzi, Silvio

AU - Cadeddu, Chiara

AU - Kheiraoui, F

AU - Iaccarino, L

AU - Pierotti, F

AU - Palla, I

AU - Veneziano, Maria Assunta

AU - Gliubizzi, Maria Daniela

AU - Sferrazza, Antonella

AU - Nicolotti, Nicola

AU - Porcasi, R

AU - La Torre, Giuseppe

AU - Di Pietro, Maria Luisa

AU - Ricciardi, Walter

PY - 2014

Y1 - 2014

N2 - Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy.

AB - Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy.

KW - HTA

KW - Lupus

KW - HTA

KW - Lupus

UR - https://publicatt.unicatt.it/handle/10807/64076

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84907395711&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907395711&origin=inward

U2 - 10.1155/2014/704207

DO - 10.1155/2014/704207

M3 - Article

SN - 2314-6133

VL - 2014

SP - 704207

EP - 704215

JO - BioMed Research International

JF - BioMed Research International

IS - N/A

ER -

Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this